Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corticosteroid plus dupilumab for IgG4-related disease with coexisting allergic disease
jRCTs031250279Recruiting
- Sponsor
- Chiba University Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dupilumab and corticosteroids in IgG4-related disease (IgG4-RD), sponsored by Chiba University Hospital. Primary endpoint: Remission with corticosteroid-free status at 52 weeks. Started Aug 2025; status: recruiting.
02
Drugs
dupilumabcorticosteroids
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on jRCTs031250279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250279.